Galliford Try Holdings PLC (LSE:GFRD) has been appointed to the complex element of Yorkshire Water's new Non-Infrastructure Works framework, covering the AMP8 delivery period (2025 - 2030).
The complex part of the framework is valued at £850 million and is expected to be worth around £100 million to Galliford Try, which will provide civil engineering, Mechanical, Electrical, Instrumentation, Control and Automation (MEICA) and building capability.
Gold producers should be doing well with the price of the precious metal within touching distance of its all-time high.
Thor Explorations has had some bumps in the road in the past twelve months, but a share price nudging towards its high for the year suggests the Nigerian-based gold miner is back on track and taking full advantage.
Cordiant Digital Infrastructure Ltd (LSE:CORD) told investors that its acquisition of Belgian data centre assets remains on-track to close in the first quarter, as it secures key approvals in Europe.
The proposed deal has received necessary regulatory approvals from Belgium's Interfederal Screening Authority under foreign direct investment legislation and from Ireland's Competition and Consumer Protection Commission.
Eco (Atlantic) Oil & Gas Ltd (AIM:ECO, TSX-V:EOG) has completed its transaction with Africa Oil Corp (TSX:AOI), which saw the sale of 1% of Block 3B/4B.
The AIM-quoted firm’s stake has reduced to 5.25% as a result.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) said it has moved into a net cash position after what it said was another strong production quarter.
Some 24,662 ounces of gold was poured from the Segilola gold mine in Nigeria during the fourth quarter of 2024. bringing the total for the year to 85,057oz.
hVIVO PLC (AIM:HVO), a company specialising in testing treatments for infectious diseases, has completed a pilot study that could help its clients develop vaccines and medicines for human metapneumovirus (hMPV), a respiratory illness with no approved treatment.
The work, carried out at hVIVO’s research facility in London, tested a safe version of the virus on healthy volunteers. The results showed the virus caused clear symptoms and infection, proving it can be used to test potential treatments.